News | April 25, 2007

Cardiologist Launches New Heart Supplements

April 26, 2007 — Cardiologist Lee A. Surkin, M.D., FAAC, is set to launch a new line of cardiac nutritional supplements this July. He says the new Cardiac Wellness Supplements are designed to complement, not replace, standard cardiovascular disease prevention and treatment therapies.

"Simply put, I developed Cardiac Wellness Supplements out of necessity," said Dr. Surkin. "I believe in an integrative approach to the prevention and treatment of cardiovascular disease. That means traditional medical care, exercise, and basic nutrition. As my patients became more educated, they asked me for recommendations for supplements to help improve their nutrition. I wasn't able to find the right supplements to meet their needs, so I developed my own proprietary line of products that I am now bringing to a broader market."

"Supplements are a worrisome area for many physicians because in most cases there is a real lack of solid scientific data to support safety or outcome," said Dr. Surkin. "As I looked at products available in the marketplace, I found few suitable options. And of the products I was comfortable recommending, expense was almost always an obstacle. Now, with my Wellcor Products, I can comfortably recommend products that have data to support them and are cost-effective."

Dr. Surkin utilized his training in human nutrition and cardiology to develop Cardiac Wellness Supplements, focusing on ingredients that have substantial scientific data on safety, efficacy and dosage. The product line will include five products: Wellcor Defense -- Omega 3, Wellcor Energize -- Supreme Green Tea, Wellcor Guard -- Resveratrol / Quercitin, Wellcor Strength -- CoEnzyme Q10 / Hawthorn and Wellcor Control -- Alpha-Lipoic Acid / L- Carnitine.
For more information visit www.cardiacwellness.com.

Related Content

Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals | September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals | September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals | May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals | May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Overlay Init